CHRO AMEX
Channel Therapeutics Corporation
1W: +11.6%
1M: +89.2%
3M: +62.8%
1Y: +89.2%
$1.35
Last traded 2025-07-28 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$8.9M
52W Range1.2301-54.29
Volume193,120
Avg Volume76,399
Beta3.29
Dividend—
Analyst Ratings
Company Info
CEOFrancis Knuettel II,
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2024-02-16
Websitechanneltherapeutics.com
4400 Route 9 South
Freehold, NJ 07728
US
Freehold, NJ 07728
US
732-514-2636
About Channel Therapeutics Corporation
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Simmons Chia-Lin | A-Award | 25,000 | $1.35 | 2025-04-11 |
| Francis Knuettel II | A-Award | 53,988 | $1.35 | 2025-04-11 |
| Davis Todd C | A-Award | 49,605 | $0.64 | 2024-11-13 |
| Malamut Richard | A-Award | 24,533 | $0.64 | 2024-11-13 |
| Friedberg Ezra M | A-Award | 24,533 | $0.64 | 2024-11-13 |